Orientations du CEPS et nouvel accord-cadre, une avancée de concert sur le prix des innovations ?

Published date05 March 2021
Subject MatterLife Sciences,EU,Prescription Drugs,France,Food & Drug Regulations,Pharmaceutical Industry,Drug Design
AuthorCharlotte Damiano
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT